Skiplinks

Medicine put to the test

As an independent scientific institute, IQWiG examines the benefits and harms of medical interventions for patients. We provide information about the advantages and disadvantages of examination and treatment methods in the form of scientific reports and easily understandable health information.

Latest news

Press Releases

Press Releases

Measurement of fractional flow reserve offers advantages for certain patients with CHD

2017-01-09 Patients in whom the widening of blood vessels by means of percutaneous coronary intervention is planned benefit from the new diagnostic procedure; this is not the case for stable CHD.  read more Link to "Measurement of fractional flow reserve offers advantages for certain patients with CHD"

IQWiG’s results on AMNOG at a glance

2017-01-04 In future IQWiG will publish press releases only for selected dossier assessments. A table available in the IQWiG press centre shows all assessment results at a glance.  read more Link to "IQWiG’s results on AMNOG at a glance"

Bronchial carcinoma: added benefit of crizotinib not proven

2017-01-02 The dossier contains no data or no suitable data on ROS1-positive, advanced non-small cell lung cancer. Results on ALK-positive tumours are not applicable.  read more Link to "Bronchial carcinoma: added benefit of crizotinib not proven"

Biomarker tests in breast cancer: decision on chemotherapy remains difficult

2016-12-05 Omitting chemotherapy can lead to more cases of distant metastasis and deaths. It cannot yet be judged whether this risk outweighs the chemotherapy-related burden.  read more Link to "Biomarker tests in breast cancer: decision on chemotherapy remains difficult"

loading …

Current commenting procedures (Hearings)

Current commenting procedures (Hearings)

No. Title Type Deadline
V16-02 Search for guidelines for the update of the DMP “type 1 diabetes” on the report plan 2017-03-21
P15-02 Invitation and decision aid for cervical cancer screening on the preliminary report 2017-03-14
V16-03 Search for guidelines for the update of the DMP “coronary heart disease” on the report plan 2017-03-10

Commissions advertised

Commissions advertised

Currently no commissions advertised.


Easily understandable information for patients and the general community

Cabozantinib (Cabometyx) for advanced renal cell cancer

The drug cabozantinib (trade name: Cabometyx) has been approved in Germany since September 2016 for the treatment of advanced renal cell cancer.  read more (Link to "Cabozantinib (Cabometyx) for advanced renal cell cancer" – opens in a new window)

to top

Glossary entries